Encontrados 15 documentos, a visualizar página 1 de 2

Ordenado por Data

Different ability of multidrug-resistant and-sensitive counterpart cells to rel...

Sousa, D; Lima, RT; Lopes-Rodrigues, V; Gonzalez, E; Royo, F; Xavier, CPR; Falcón-Pérez, JM; Vasconcelos, MH

Cancer multidrug resistance (MDR) is one of the main challenges for cancer treatment efficacy. MDR is a phenomenon by which tumor cells become resistant to several unrelated drugs. Some studies have previously described the important role of extracellular vesicles (EVs) in the dissemination of a MDR phenotype. EVs’ cargo may include different players of MDR, such as microRNAS and drug-efflux pumps, which may be...


Synthesis of novel methyl 3-(Hetero)arylthieno[3,2-b]pyridine-2-carboxylates an...

Silva, BR; Rebelo, R; Rodrigues, JM; Xavier, CPR; Vasconcelos, MH; Queiroz, MJRP

A series of novel functionalized methyl 3-(hetero)arylthieno[3,2-b]pyridine-2-carboxylates 2a–2h were synthesized by C-C Pd-catalyzed Suzuki-Miyaura cross-coupling of methyl 3-bromothie-no[3,2-b]pyridine-2-carboxylate with (hetero)aryl pinacol boranes, trifluoro potassium boronate salts or boronic acids. Their antitumoral potential was evaluated in two triple negative breast cancer (TNBC) cell lines—MDA-MB-231 ...


Drug repurposing opportunities in pancreatic ductal adenocarcinoma

Rebelo, R; Polónia, B; Santos, LL; Vasconcelos, MH; Xavier, CPR

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest tumors worldwide. The diagnosis is often possible only in the latter stages of the disease, with patients already presenting an advanced or metastatic tumor. It is also one of the cancers with poorest prognosis, presenting a five-year survival rate of around 5%. Treatment of PDAC is still a major challenge, with cytotoxic chemotherapy re...


Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, ne...

Vanden Eynde, JJ; Mangoni, AA; Rautio, J; Leprince, J; Azuma, YT; García-Sosa, AT; Hulme, C; Jampilek, J; Karaman, R; Li, W; Gomes, PAC


Urinary biomarkers in bladder cancer: Where do we stand and potential role of e...

Oliveira, MC; Caires, HR; Oliveira, MJ; Fraga, A; Vasconcelos, MH; Ribeiro, R

Extracellular vesicles (EVs) are small membrane vesicles released by all cells and involved in intercellular communication. Importantly, EVs cargo includes nucleic acids, lipids, and proteins constantly transferred between different cell types, contributing to autocrine and paracrine signaling. In recent years, they have been shown to play vital roles, not only in normal biological functions, but also in pathol...


The Role of Extracellular Vesicles in the Hallmarks of Cancer and Drug Resistance

Xavier, CPR; Caires, HR; Barbosa, MAG; Bergantim, R; Guimarães, JE; Vasconcelos, MH

Extracellular vesicles (EVs) mediate intercellular signaling and communication, allowing the intercellular exchange of proteins, lipids, and genetic material. Their recognized role in the maintenance of the physiological balance and homeostasis seems to be severely disturbed throughout the carcinogenesis process. Indeed, the modus operandi of cancer implies the highjack of the EV signaling network to support tu...


Deep sequencing analysis reveals distinctive non-coding RNAs when comparing tum...

Sousa, D; Matthiesen, R; Lima, RT; Vasconcelos, MH

Multidrug resistance (MDR) is one of the main limitations of cancer treatment. The overexpression of drug-eux pumps, such as P-glycoprotein (P-gp), is a major cause of MDR. Importantly, di erent studies have shown that extracellular vesicles (EVs) participate in the communication between MDR cells and drug-sensitive counterparts, promoting dissemination of the MDR phenotype. In the present work, we aimed to ide...


Multiple myeloma: Available therapies and causes of drug resistance

Pinto, V; Bergantim, R; Caires, HR; Seca, H; Guimarães, JE; Vasconcelos, MH

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies. Survival outcomes have improved substantially due to the introduction of many of these drugs allied with their rational use. Nonetheless, MM patients successively relaps...


Preliminary virtual screening studies to identify grp78 inhibitors which may in...

Palmeira, A; Sousa, E; Köseler, A; Sabirli, R; Gören, T; Türkçüer, I; Kurt, Ö; Pinto, MM; Vasconcelos, MH

SARS-CoV-2 Spike protein was predicted by molecular docking to bind the host cell surface GRP78, which was suggested as a putative good molecular target to inhibit Covid-19. We aimed to confirm that GRP78 gene expression was increased in blood of SARS-CoV-2 (+) versus SARS-CoV-2 (-) pneumonia patients. In addition, we aimed to identify drugs that could be repurposed to inhibit GRP78, thus with potential anti-SA...


Design and synthesis of new inhibitors of p53–MDM2 interaction with a chalcone ...

Pereira, D; Lima, RT; Palmeira, A; Seca, H; Soares, J; Gomes, S; Raimundo, L; Maciel, C; Pinto, M; Sousa, E; Vasconcelos, MH; Saraiva, L; Cidade, H

The virtual screening of a library of chalcone derivatives led us to the identification of potential new MDM2 ligands. The chalcones with the best docking scores obeying the Lipinski rule of five were subsequently prepared by base-catalyzed aldol reactions. The activity of these compounds as inhibitors of p53–MDM2 interaction was investigated using a yeast-based screening assay. Using this approach two chalcone...


15 Resultados

Texto Pesquisado

Refinar resultados

Autor





















Data





Tipo de Documento


Tipo de acesso


Recurso


Assunto